FDA approval for new drugs has recently passed in April.

Lung Cancer Breast Cancer Renal Cancer Bladder Cancer Clinics are actively developing new drugs compared to other cancer types. As research continues, target therapies and immunotherapies are developing. This increases the patient's survival time and secures more time. We strive to benefit new drugs that are developed every day and many cancer patients. The United States has recently ratified the New Testament in April.

I will tell you the good news.

1. MEK is a promising news for the treatment of NF1 neurofibroma suppressing.

Selimetinib (AZD6244), which passed the FDA ratification on April 1, 2019, is a treatment for patients with neurofibroma of 3 years or older who can not be operated on with MEK inhibitor. 

2. Palbociclib is applicable to HR + / HER2-male breast cancer patients. 

On April 4, 2019, the FDA approved Palbociclib with hormone therapy. Hormone receptor (HR) positive HER2 negative end stage or metastatic male breast cancer patients. 

3. The new immunotherapy, Tebentafusp, has passed approval for metastatic uveal melanoma. 

On April 11, 2019, the FDA promptly approved tebentafusp (IMCgp100) based on Phase 1 results. This has been approved for patients with HLA-A * 0201-positive prostate cancer. The 1-year survival rate was 74%, the median follow-up period was 15.9 months, and the overall survival rate was not confirmed. 

4. Approved PD-L1> = 1% pembrolizumab in non-small cell lung cancer. 

On April 11, 2019, the FDA expanded its application to non-small cell lung cancer (NSCLC) in patients with stage III non-small cell lung cancer (NSCLC) that can not undergo surgery or radiation therapy, including prostate therapy or metastasis.

In patients with non-small cell lung cancer, PD-L1 expression levels are above 1% on average, but not for EGFG or ALK mutations.

5. Erdafitinib has passed approval for bladder cancer patients. 

On April 12, 2019, Erdafitinib (Balversa) has passed FDA approval for the treatment of end stage or metastatic bladder cancer patients. It is a platinum chemotherapy developed from FGFR3 or FGFR2. It is the first target cure for patients with metastatic bladder cancer. 

6. In combination with pemizumab and axitinib for the treatment of renal cancer 

On April 22, 2019, the FDA approved the use of pembrolizumab and axitinib in patients with kidney cancer. These results, compared with sunitinib, are based on results from the KEYNOTE-426 Stage 3 experiment, and concomitant therapy improved statistical survival and overall survival rates. 

7. PD-L1 (IHC 22C3 pharmDX) for the evaluation of pemizumab in non-small cell lung cancer 

April 17, 2019 The FDA is expanding the use of PD-L1 22C3 pharmDX for use as a primary treatment for pembrolizumab in patients with stage 3 or metastatic non-small cell lung cancer.

This expanded scope is approved by the FDA approved standard of pembrolizumab as the primary treatment for patients with stage III or metastatic non-small cell lung cancer. TPS average> = 1% EGFR and ALK are not applicable.

Research and release of new drugs are ongoing. It is a hope for cancer patients and a driving force in life. However, further research is needed to see if these new drugs are right for you. As we all know, wrong treatment can have irreversible consequences. Inaccurate medical information Cancer may result in conditions that can no longer be treated.

 Therefore, if you want to use cancer drugs with the right information for your cancer patients, you should consult a wealth of experienced professionals. You need to use the anticancer drugs through your physical condition and accurate medical information to prevent the side effects of drugs and to see higher efficacy.